Quick Answer
X4 Pharmaceuticals, Inc reported Stockholders Equity of $186.29 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed an increase of +741.1% in Stockholders Equity from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$51.81 million | Q2 2018: -$57.69 million | Q3 2018: -$66.09 million | Q1 2019: $29.44 million | Q2 2019: $96.17 million | Q3 2019: $79.11 million | Q1 2020: $118.79 million | Q2 2020: $104.88 million | Q3 2020: $89.71 million | Q1 2021: $105.06 million | Q2 2021: $87.34 million | Q3 2021: $68.68 million | Q1 2022: $49.71 million | Q2 2022: $30.07 million | Q3 2022: $61.85 million | Q1 2023: $51.68 million | Q2 2023: $67.54 million | Q3 2023: $67.59 million | Q1 2024: $1.04 million | Q2 2024: $94.45 million | Q3 2024: $59.62 million | Q1 2025: $22.94 million | Q2 2025: $3.97 million | Q3 2025: $61.62 million.
- Over the full 11 years of available data (2015 to 2025), X4 Pharmaceuticals, Inc's Stockholders Equity has grown by 642.8%.
- Historical annual values: Fiscal year 2025: $186.29 million | Fiscal year 2024: $22.15 million | Fiscal year 2023: $51.10 million | Fiscal year 2022: $74.05 million | Fiscal year 2021: $64.41 million | Fiscal year 2020: $72.80 million | Fiscal year 2019: $129.22 million | Fiscal year 2018: -$77.09 million | Fiscal year 2017: -$44.55 million | Fiscal year 2016: -$23.05 million | Fiscal year 2015: -$34.32 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: